Phase 2 Study of Cemiplimab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Final Analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. J of Skin 2023, 7 (2), s176. https://doi.org/10.25251/skin.7.supp.176.